*Development of modern biotechnological products for rapid and effective diagnosis of serious and atypical respiratory infections.
Project goals
*Development of modern and certied in-vitro diagnostic kits for molecular detection of Mycobacterium tuberculosis, Chlamydia pneumoniae and Legionella pneumophilla, microorganisms, which are considered to be the most important agents causing serious atypical respiratory diseases in human. These diagnostic kits shall utilize the most modern technology of nucleic acid amplification using the "real-time" polymerase chain reaction (PCR) method.
Keywords
respiratory diseasesMycobacterium tuberculosisChlamydia pneumoniaeLegionella pneumophillapolymerase chain reactionPCRreal-time PCRin vitro diagnosticsIVDbiotechnology
Public support
Provider
Ministry of Industry and Trade
Programme
TANDEM
Call for proposals
TANDEM 3 (SMPO200600002)
Main participants
—
Contest type
VS - Public tender
Contract ID
FT-TA3/098
Alternative language
Project name in Czech
*Vývoj moderních biotechnologických produktů pro rychlou a účinnou diagnostiku původců závažných a atypických respiračních onemocnění.
Annotation in Czech
*Vývoj moderní a certifikované soupravy určené pro in vitro DNA diagnostiku původců závažných a atypických respiračních onemocnění Mycobacterium tuberculosis, Chlamydia pneumoniae a Legionella pneumophilla. Vyvinuté diagnostické soupravy budou využívat moderní technologii amplifikace nukleových kyselin metodu "real-time" polymerázové řetězové reakce (PCR).
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
FN - Epidemiology, infection diseases and clinical immunology
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
—
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30302 - Epidemiology
30303 - Infectious Diseases
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The technology of detection of three respiratory pathogens as well as prototypes of in vitro diagnostic devices for their detection in clinical samples are main results of the project. The prototype composition is protected as utility model.
Solution timeline
Realization period - beginning
Mar 1, 2006
Realization period - end
Dec 31, 2009
Project status
U - Finished project
Latest support payment
Mar 25, 2009
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP10-MPO-FT-U/01:1
Data delivery date
Jun 21, 2010
Finance
Total approved costs
27,301 thou. CZK
Public financial support
9,075 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
18,227 thou. CZK
Basic information
Recognised costs
27 301 CZK thou.
Public support
9 075 CZK thou.
33%
Provider
Ministry of Industry and Trade
CEP
FN - Epidemiology, infection diseases and clinical immunology
Solution period
01. 03. 2006 - 31. 12. 2009